In Quest of Better Clinicopathologic Correlation in the Diagnosis of Dementia:The Florida Cognitive Assessment
Main Article Content
Abstract
Introduction: Clinical evaluation of dementia, even by experts, is neither systematic nor optimal and provides a demonstrably inadequate basis for diagnosis of specific underlying pathologies. Post-mortem pathologic evaluation also has serious limitations. As a result, clinicopathologic correlation, even with Alzheimer’s disease and even in a 2024 study, was only 71%. Thus, there is a pressing need for a bedside cognitive evaluation instrument that can potentially improve the accuracy of clinical evaluation. This paper introduces such an instrument, the Florida Cognitive Assessment.
Methods: The Florida Cognitive Assessment was designed by a group of experts in behavioral neurology with the aim of providing a profile of cognitive impairment rather than just a score. Over the years, it has been refined on the basis of clinical experience to take maximal advantage of all observed patient behaviors that could signal impairment in particular cognitive domains. Tests specific to all of the most common dementias are included.
Results and Discussion: In clinical practice, the Florida Cognitive Assessment, a test that requires 10-15 minutes to administer, has proven to be an invaluable tool in fully characterizing the nature of the cognitive profile and in quickly arriving at a diagnosis of a specific type of dementia that is fully congruent with established criteria. Results have also been congruent with those of neuropsychological testing carried out in particular individuals. The Florida Cognitive Assessment has not been empirically validated. The only truly adequate validation would be in terms of post-mortem neuropathology. Psychometric properties could be quantified and correlation of some test results with those of neuropsychological assessment is feasible.
Conclusions: The Florida Cognitive Assessment has already proven to be a very useful tool in providing a means for rapid assessment of the specific domains of impairment in particular individuals with dementia. It has the theoretical potential for substantially improving clinicopathologic correlation.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Brun A, Gustafson L. Distribution of cerebral degeneration in Alzheimer’s disease. A clinicopathologic study. Arch Psychiat Nervenkr. 1976;223:15-33.
3. Nadeau SE. Neural population dynamics and cognitive function. Front Hum Neurosci. 2020;14:50. Doi: 10.3389/fnhum.2020.00050
4. Nadeau SE. Language and aphasias. Continuum. 2021;27(6):1549-1561.
Doi: 10.1212/CON.0000000000001058
5. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006-1015. Doi:10.1212/WNL.0b013e31821103e6
6. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dementia. 2018;14(4):535-562.
Doi: 10.1016/j.jalz.2018.02.018
7. Petersen RC, Weintraub S, Sabbagh M, et al. A new framework for dementia nomenclature. JAMA Neurology. 2023.
Doi: 10.1001/jamaneurol.2023.3664
8. Nasreddine Z. Montreal Cognitive Assessment. 2010. https://www.dochub.com/jsfiller-desk13/?flat_pdf_quality=low&mode=cors&requestHash=adb7f1df17c0a2df8183135d0f501601678bf4cd51c43bf59dcf29a847395bde&lang=en&projectId=1534743711&PAGE_REARRANGE_V2_MVP=true&richTextFormatting=true&isPageRearrangeV2MVP=true&jsf-page-rearrange-v2=true&jsf-dss-v2=false&LATEST_PDFJS=true&jsf-document-scroll-zoom=true&jsf-redesign-full=true&act-notary-pro-integration=true&jsf-pdfjs-fourth=false&jsf-fake-edit-embedded=false&isSkipEditorLoadFrequency=true&routeId=6a49abfc670ea77b4c86e7788c817034#90ac1b990d6f4720bb5d66f17972116a.
9. Kapasi A, Yu L, Stewart CS, Schneider JA, Bennett DA, Boyle PA. Association of TDP-43 pathology with domain specific literacy in older persons. Alzheimer Dis Assoc Disord. 2019;33(4):315-320. Doi:10.1097/WAD.0000000000000334
10. Gil MJ, Manzano MS, Cuadrado ML, et al. Frontotemporal lobar degeneration: Study of a clinicopathological cohort. J Clinical Neurosc. 2018;58:172-180.
Doi: 10.1016/j.jocn.2018.10.024
11. Nadeau SE. Neural mechanisms of emotions, alexithymia, and depression. Handb Clin Neurol. 2021;183:299-314. Doi: 10.1016/B978-0-12-822290-4.00014-1
12. Boeve BF. Behavioral variant frontotemporal dementia. Continuum. 2022;28:702-725. Doi:10.1212/CON.0000000000001105
13. Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9:40. Doi:10.1038/s41572-023-00447-0
14. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374:609-619. Doi: 10.1016/S0140-6736(09)60879-5
15. Steffens DC. Treatment-resistent depression in older results. N Engl J Med. 2024;390:630-639. Doi:10.1056/NEJMcp2305428
16. Andersson EM, Hoff EJ, Waldö ML, Englund E. Clinicopathological concordance in cognitive disease diagnostics. Clin Neuropathol. 2020;39(3):99-104. Doi: 10.5414/NP301204
17. Selvackadunco S, Langford K, Shah Z, et al. Comparison of clinical and neuropathological diagnosesof neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. J Neural Transm. 2019;126:327-337. Doi:10.1007/s00702-018-01967-w
18. Mehta RI, Sch eider JA. What is ‘Alzheimer’s disease’? The neuropathological heterogeneity of clinically defined Alzheimer’s disease. Curr Opin Neurol. 2021;35:237-245. Doi:10.1097/WCO.0000000000000912
19. Adler CH, Beach TG, Zhang N, et al. Unified staging system for Lewy body disorders: clinicopathologic correlations and comparison to Braak staging. J Neuropath Exp Neurol. 2019;78(10):891-899. Doi:10.1093/jnen/nlz080
20. Bolsewig K, Annemartijn AJMvU, Blujdea ER, et al. Association of plasma amyloid, p-tau, GFAP, and Nfl with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies. Neurology. 2024;102:e209418. Doi:10.1212/WNL.0000000000209418
21. Beach TG, Malek-Ahmadi M. Alzheimer’s diease neuropathologic cormorbidities are common in the young old. J Alzheimer Dis. 2021;79:389-400. Doi:10.3233/JAD-201213
22. Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83. Doi:10.1002/ana.25123
23. Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Arch Neurol. 2005;65(3):376-382. Doi:10.1212/01.wnl.0000168877.06011.15
24. Price CC, Mitchell SM, Brumback B, et al. MRI-leukoaraiosis thresholds and the phenotypic expression of dementia. Neurology. 2012;79:734-740. Doi:10.1212/WNL.0b013e3182661ef6
25. James BD, Wilson BA, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain 2016;139(11):2983-2993. Doi:doi:10.1093/brain/aww224
26. Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Lisesinger AM. TAR DNA-binding protein 43 and pathological subtype of Alzheimer’s disease impact clinical features. Ann Neurol. 2015;78:697-708. Doi:10.1002/ana.24493
27. Chin NA, Erickson CM. Alzheimer’s disease, biomarkers, and mAbs — what does primary care need? N Engl J Med. 2024;390(24):2229-2231. Doi:10.1056/NEJMp2401854
28. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. Doi:10.1056/NEJMoa2212948
29. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease .The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. Doi:10.1001/jama.2023.13239
30. Nadeau SE. Lecanemab questions. Neurology. 2024;102:e209320.
Doi: 10.1212/WNL.0000000000209320
31. Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood biomarkers to detect Alzheimer disease in praimary and secondary care. JAMA. 2024. Doi:10.1001/jama.2024.13855
32. Luria AR. Higher Cortical Functions in Man. Second ed. New York: Basic Books; 1984.
33. Bálint R. Seelenlahmung des "Schauens", optische Ataxie, raumliche Störung der Aufmerksamkeit. Monatsschrift Psychiatrie Neurologie. 1909;25:57-71.
34. Francis WN, Kucera H. Frequency analysis of English usage: lexicon and grammar. Boston: Houghton Mifflin; 1982.
35. L’hermitte F. "Utilization behavior" and its relation to lesions of the frontal lobes. Brain. 1983;106:237-256. Doi:10.1017/S1355617709991469
36. Lhermitte F, Pillon B, Serdaru M. Human autonomy and the frontal lobes. Part I: Imitation and utilization behavior: a neuropsychological study of 75 patients. Ann Neurol. 1986;19:326-334. Doi:10.1002/ana.410190404
37. Cosentino S, Jefferson A, Chute DL, Kaplan E, Libon DJ. Clock drawing errors in dementia. Neuropsychological and neuroanatomical consideratons. Cog Behav Neurol. 2004;17(2):74-84. Doi: 10.1097/01.wnn.0000119564.08162.46
38. Luria AR, Tsvetkova LS. The programming of constructive activity in local brain injuries. Neuropsychologia. 1964;2:95-107.
39. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351:56-67. Doi: 10.1056/NEJMra040223
40. Yong KXX, Graff-Radford J, Ahmed S, et al. Diagnosis and management of posterior cortical atrophy. Current Treatment Options in Neurological Disease. 2023;25:23-43. Doi:10.1007/s11940-022-00745-0
41. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol. 2008;63:709-719. Doi:10.1002/ana.21388
42. Nadeau SE. The Neural Architecture of Grammar. Cambridge: MIT Press; 2012.
43. Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 2007;6:1004-1014. Doi:10.1016/S1474-4422(07)70266-1
44. Shir D, Pham NTT, Botha H, et al. Clinicoradiologic and neuropathologic evaluation of corticobasal syndrome. Neurology. 2023;101:e289-e299. Doi:10.1212/WNL.0000000000207397
45. Mayo MC, Bordelon Y. Dementia with Lewy Bodies. Seminars in Neurology. 2014;34:182-188. Doi:10.1055/s-0034-1381741
46. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100. Doi:10.1016/S1474-4422(07)70266-1
47. Arts NJM, Walvoort SJW, Kessels RPC. Korsakiff’s syndrome: a critical review. Neuropsychiatr Dis Treat. 2017;13:2875-2890. Doi:10.2147/NDT.S130078
48. Bolandzadeh N, Davis JC, Tam R, Handy TC, Liu-Ambrose T. The association between cognitive function and white matter lesion location in older adults: a systematic review. BMC Neurol 2012;12:126. Doi:10.1186/1471-2377-12-126
49. SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553-561. Doi:10.1001/jama.2018.21442
50. Nadeau SE. Bilingual aphasia: explanations in population encoding. J Neurolinguistics. 2019;49:117-143.
Doi 10.1016/j.jneuroling.2018.10.002